Definitive Contract HHSN261200522015C

<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by a U.S. government agency to Provid Pharmaceuticals Inc., a for-profit organization, in the amount of $199,922.00. The contract is for &quot;Medicinal Chemistry Lead Optimization&quot; research, with a completion date of June 29, 2007. The contract is a Firm Fixed Price Definitive Contract, with the place of performance being North Brunswick Township, NJ.</p>

This is a $300,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Coordination Pharmaceuticals Inc., a small business. The contract is for the detection, diagnosis, treatment, prevention, and research of pediatric cancers and/or rare cancers. It was awarded under a Small Business Innovation Research (SBIR) Concept Award Program, which is a &quot;Phase 0&quot; pilot program intended to encourage small businesses to develop innovative and...

This is a $2,247,942.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian federal agency. The contract, awarded to Pics, Inc., a for-profit S corporation, is for the development of CERTAS, a researcher configurable self-monitoring system. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type and has an ultimate completion date of June 30, 2007. This SBIR Phase II contract builds on an earlier SBIR...

This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...

This is a Cost Plus Fixed Fee contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Medavante, Inc., a small business, under the Small Business Innovation Research (SBIR) Program Phase II. The contract, valued at $625,055.25, is for research and development in physical science. The contract has a period of performance through September 16, 2011. This contract is a definitive contract, indicating it is a stand-alone award rather than being associated with a larger...

<p>This is a cost-plus-fixed-fee SBIR Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to LP Therapeutics, Inc. for the development of novel therapeutic agents targeting cancer stem cells. The contract has a total ceiling value of $1,489,000.12 and a period of performance ending on March 18, 2019. The contract was set aside for small businesses. No information is provided about major subcontractors.</p>

<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>

<p>This is a $994,198.78 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Precision For Medicine (TX), Inc. on September 20, 2013. The contract is for research and development in biomedical (basic research) and has a period of performance through September 19, 2015. The contract is designated as a total small business set-aside.</p>

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

<p>This is a $1,496,276.00 Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a civilian agency, to Cellerant Therapeutics, Inc. The contract is for the SBIR (Small Business Innovation Research) Phase II development of novel therapeutic agents that target cancer stem cells, under Topic 326. The contract has a total small business set-aside designation and was awarded on September 19, 2016 with an ultimate completion date of April 16, 2018.</p>